EIKON THERAPEUTICS INC

Shares of Eikon Therapeutics rise 3% to $7.26, staying below its 200‑day MA while peers swing, offering investors a chance for further upside if clinical milestones hit.

Investors eye Eikon Therapeutics (EIKN) as it heads to the ESMO Congress, but thin volume, a price below its 200‑day SMA and a recent 12.8% decline warn that a breakthrough, not hype, will be needed for a rally.